Investor Relations

2018 News Releases

Webcast ImageWebcast
Millendo Therapeutics, Inc. at Oppenheimer 29th Annual Healthcare Conference (Replay)
03/19/19 at 3:55 p.m. ET
Millendo Therapeutics, Inc. at Oppenheimer 29th Annual Healthcare Conference
Tuesday, March 19, 2019 3:55 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle  
12/07/18Millendo Therapeutics Announces Successful Merger Completion
– Merger with OvaScience Closed – – Shares of Combined Company to Commence Trading on the Nasdaq Capital Market Under New Symbol “MLND” on Monday, December 10th, 2018 – – Proceeds of $85.4 Million to Fund Orphan Endocrine Pipeline – – Pivotal Phase 2b/3 Trial for Prader-Willi Syndrome Initiating in 1Q19 – ANN ARBOR, Mich.--(BUSINESS WIRE)--Dec. 7, 2018-- Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stag... 
 Printer Friendly Version
11/14/18Millendo Therapeutics Strengthens Executive Team with Key Appointments
... 
Printer Friendly Version
11/01/18OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing
... 
Printer Friendly Version
09/25/18Millendo Therapeutics Appoints Habib Dable to Its Board of Directors
... 
Printer Friendly Version
09/13/18Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of Nevanimibe in Patients with Classic Congenital Adrenal Hyperplasia
... 
Printer Friendly Version
08/10/18Millendo Therapeutics to Participate in Upcoming Investor Conferences
... 
Printer Friendly Version
08/09/18OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
... 
Printer Friendly Version
06/28/18Millendo Therapeutics Appoints Dr. Ryan Zeidan as Senior Vice President, Development and Strengthens Leadership Team with Key Promotions
... 
Printer Friendly Version
03/15/18Millendo Therapeutics to Present at the Oppenheimer 28th Annual Healthcare Conference
... 
Printer Friendly Version
03/07/18Millendo Therapeutics Announces Data Presentation for Nevanimibe at ENDO 2018
... 
Printer Friendly Version
01/03/18Millendo Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
... 
Printer Friendly Version